Aklog Lishan 4

What Happened Aklog Lishan, Chairman and CEO of PAVmed Inc. (PAVM), was granted 350,000 restricted shares on 2026-04-02. The grant was reported at $0.00 per share on the Form 4 (aggregate reported value $0), reflecting an equity award rather than a cash purchase or sale. This is an award/grant (transaction code A) under the company’s long-term incentive plan.

Key Details

• Transaction date: 2026-04-02; Form 4 filed 2026-04-03 (timely filing).
• Grant: 350,000 restricted common shares; reported price $0.00 (aggregate $0).
• Vesting: Single vesting date of May 20, 2029; shares are subject to forfeiture if required service is not completed (see footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Related footnotes:
  • F1: Award granted under the Issuer’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan; single vest date 5/20/2029.
  • F2/F3: Dr. Aklog disclaims beneficial ownership of securities held by Pavilion Venture Partners LLC (of which he is sole manager) and HCFP/AG LLC (co-manager), except for his pecuniary interest.

Context This filing documents an equity award to the CEO — common compensation for executives to align incentives with long-term company performance. Because these are restricted shares with a future vest date and possible forfeiture, they do not represent immediately tradable stock or a cash transaction.